Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (Prothrombin, and Factors V, VIII, IX and X), which are involved in a blood coagulation cascade leading to the formation of insoluble fibrin clots and the promotion of platelet aggregation.
Coagulation Factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406aa, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor.
Factor IXa, Factor Xa, Factor XIIa, or Thrombin mediated proteolytic cleavage of Factor VII at Arg152-Ile153 generates Factor VIIa, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains.
Coagulation Factor XIII is a terminal effector in the blood coagulation cascade.
Plasma Factor XIII is a heterotetramer composed of two A subunits and two B subunits.
The A subunits have catalytic function, and the noncatalytic B subunits may serve as plasma carrier molecules.
Applications:Suitable for use in Western Blot.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:1000Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.3, 0.05% sodium azide.
Specificity：Recognizes endogenous levels of human F13A1 protein. Species Crossreactivity: mouse and rat
Isotype：IgG
Calc Applications Abbrev：WB
Calc Crossreactivity：Hu Mo Rt
Immunogen：Synthetic peptide corresponding to human F13A1.
